Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lallena

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
Cancer Cell|December 13, 2017
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor AbemaciclibXueqian Gong, Lacey M Litchfield, Yue Webster, et al.
Cancer Research|December 9, 2024
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast CancerShripad V Bhagwat, Cecilia Mur, Matthew Vandekopple, et al.
Cancer Discovery|October 31, 2018
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor GeneXueqian Gong, Jian Du, Stephen H Parsons, et al.
Molecular Cancer Therapeutics|September 19, 2019
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor EfficacyJian Du, Lei Yan, Raquel Torres, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
Cancer Cell|December 13, 2017
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor AbemaciclibXueqian Gong, Lacey M Litchfield, Yue Webster, et al.
Cancer Research|December 9, 2024
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast CancerShripad V Bhagwat, Cecilia Mur, Matthew Vandekopple, et al.
Cancer Discovery|October 31, 2018
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the <i>RB1</i> Tumor Suppressor GeneXueqian Gong, Jian Du, Stephen H Parsons, et al.
Molecular Cancer Therapeutics|September 19, 2019
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor EfficacyJian Du, Lei Yan, Raquel Torres, et al.
Pageof 11